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Abstract 
Objective To investigate cost changes for health systems and participants resulting 
from switching to short treatment regimens for multidrug-resistant (MDR) 
tuberculosis. 
Methods The costs to health systems and participants of long (20 to 
22 months) and short (9 to 11 months) MDR tuberculosis regimens in Ethiopia and 
South Africa were compared. Cost data were collected from participants in the 
STREAM phase-III randomized controlled trial and we estimated health-system costs 
using bottom-up and top-down approaches. A cost–effectiveness analysis was 
performed by calculating the incremental cost per unfavourable outcome avoided. 
Findings Health-care costs per participant in South Africa were 8340.7 United 
States dollars (US$) with the long and US$ 6618.0 with the short regimen; in Ethiopia, 
they were US$ 6096.6 and US$ 4552.3, respectively. The largest component of the 
saving was medication costs in South Africa (67%; US$ 1157.0 of total US$ 1722.8) 
and social support costs in Ethiopia (35%, US$ 545.2 of total US$ 1544.3). In Ethiopia, 
trial participants on the short regimen reported lower expenditure for supplementary 
food (mean reduction per participant: US$ 225.5) and increased working hours (i.e. 
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667 additional hours over 132 weeks). The probability that the short regimen was 
cost–effective was greater than 95% when the value placed on avoiding an 
unfavourable outcome was less than US$ 19 000 in Ethiopia and less than US$ 14 500 
in South Africa. 
Conclusion The short MDR tuberculosis treatment regimen was associated 
with a substantial reduction in health-system costs and a lower financial burden for 
participants. 
Introduction 
Until recently, guidelines on multidrug-resistant (MDR) tuberculosis recommended a 
treatment period of 20 to 22 months,1 which has substantial costs for both patients and health 
services, particularly for hospitalization.2–6 A shortened treatment regimen of 9 to 11 months 
was tested in Bangladesh in 2010, with promising efficacy, and was subsequently 
implemented in several West African countries.7 However, no randomized controlled trials or 
economic evaluations have been performed. Given that health systems in many countries 
with a high MDR tuberculosis burden face resource constraints,5 there have been calls for 
more research on the economic impact of MDR tuberculosis. Moreover, global policy goals 
emphasize financial protection for patients and the elimination of catastrophic health-care 
costs.8 
The results of the phase-III, noninferiority, randomized, controlled trial, STREAM, 
were published in 2019. They demonstrated that a short MDR tuberculosis regimen of 9 to 
11 months had noninferior efficacy and comparable safety to the World Health 
Organization’s (WHO’s) approved standard regimen of 20 to 22 month (i.e. the long 
regimen).9 The trial collected data on the costs of each regimen for participants and health 
systems and on participants’ financial wellbeing.10,11 Our aim was to investigate the nature, 
magnitude and timing of the changes in costs for participants and health systems that result 
from switching to the short MDR tuberculosis regimen. As WHO’s treatment guidelines are 
undergoing rapid revision,12 we hope that our overall cost–effectiveness assessment and 
detailed cost analysis will help tuberculosis programme organizers to understand the potential 
costs and savings of transitioning to all-oral, short treatment regimens and to devise detailed 
plans for their implementation. 
Methods 
The STREAM trial’s economic evaluation compared the health-system and participant costs 
of short and long regimens for treating MDR-TB in Ethiopia and South Africa. Before the 
trial, the median treatment duration was 20 months in Ethiopia and 22 months in South 
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Africa. Trial participants were randomly assigned in a 2 : 1 ratio to the short or long regimen, 
with randomization stratified by trial site and the presence of human immunodeficiency virus 
infection.11 Data were collected at two sites in Ethiopia (i.e. St Peter’s Specialized Hospital 
and the Armauer Hansen Research Institute Hospital, both in Addis Ababa) and two in South 
Africa (i.e. Sizwe Tropical Diseases Hospital in Johannesburg and Doris Goodwin Hospital 
in Pietermaritzburg). Details of the methods are available elsewhere.11,13 
We estimated health-system costs using a mix of bottom-up and top-down 
approaches.14,15 The costs of medications, inpatient stays and serious adverse events were 
calculated for individuals and the costs of laboratory tests, electrocardiography, staff time, 
consumables and social support were based on aggregate data collected during the trial. 
Where trial data were insufficiently detailed, we obtained supplementary information on 
typical care activities, such as tuberculosis drug use and the resources involved, by reviewing 
national and local guidelines and by interviewing clinical and managerial staff.10 We 
estimated costs using relevant unit costs for each country (available in the data repository).13 
At all trial sites, participants were hospitalized from treatment initiation until sputum 
cultures tested negative. As accurate records of admission and discharge dates were 
unavailable, we used the time to sputum smear conversion as a proxy for the inpatient stay, 
allowing an additional 4 weeks for the result to be confirmed and communicated to clinicians. 
If a participant died within this period or before smear conversion, we assumed the hospital 
stay was the number of treatment days. 
We also estimated the health-care resources required to manage serious adverse 
events because these events were the most costly.16 We estimated these costs for Ethiopia and 
based them on a sample of all serious adverse events associated with MDR tuberculosis or its 
treatment.13 Tests, examinations and care activities relating to the diagnosis and management 
of these events were identified by interviewing clinical staff and reviewing case notes. 
Data on costs incurred by participants and on their socioeconomic status were 
collected at scheduled assessments between November 2012 and December 2017 in Ethiopia 
and between August 2014 and January 2018 in South Africa. The questionnaires used to 
assess participants’ costs were developed in English from the STOP-TB Partnership’s 
questionnaire,17 translated into local languages (i.e. Amharic, Zulu and Sesotho) and 
administered by the same staff who collected clinical data from trial participants. The 
questionnaires were administered 12 weeks after treatment randomization and every 
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12 weeks thereafter until the end of follow-up (i.e. 132 weeks). Information was collected on 
direct costs (e.g. food and transport) and indirect costs (e.g. lost income) incurred during the 
preceding 12 weeks. Participants were asked to estimate costs they would expect to face in 
routine care: for example, in South Africa, as free transport was provided for STREAM 
participants to attend clinic reviews, they were asked to estimate the usual cost of these trips. 
A separate questionnaire on participants’ socioeconomic characteristics was administered at 
randomization and then every 24 weeks. The number of participants at each site who 
provided data on direct costs, the cost of supplementary food and the number of hours 
worked is presented in Table 1. 
The study was approved by the International Union Against Tuberculosis and Lung 
Disease’s ethics advisory group, the South African Medical Research Council’s ethics 
committee, the Wits Health Consortium’s protocol review committee, the University of the 
Witwatersrand’s human research ethics committee, the University of Kwazulu–Natal’s 
biomedical research ethics committee, the St Peter TB Specialized Hospital’s ethical review 
committee and the Armauer Hansen Research Institute–All Africa Leprosy Rehabilitation and 
Training Hospital’s ethical review committee. All participants provided written informed 
consent. The trial registration number is ISRCTN78372190. 
Analysis 
We estimated costs in 2017 United States dollars (US$) from the perspective of the health 
system and the participant separately.18 A trial-based perspective was adopted for estimating 
participants’ costs with a 132-week time horizon. Health-system costs were calculated for 
each participant who completed treatment – no follow-up costs were included because 
patients were not routinely followed up after the end of treatment. The cost of activities 
judged by the study’s clinical experts to have been solely for research (e.g. taking samples for 
pharmacokinetic studies) were excluded.  
A cost–effectiveness analysis was performed by calculating the incremental cost per 
unfavourable outcome avoided, which was the primary efficacy outcome of the STREAM 
trial. Unfavourable outcomes were defined as: (i) starting two or more drugs not in the 
allocated regimen; (ii) extending treatment beyond its scheduled end for any reason other 
than compensating for treatment not taken (up to a maximum of 8 weeks); (iii) death from 
any cause; (iv) a positive culture result when the patient was last seen; and (v) missed 
assessment at 76 weeks.9 Decision uncertainty was captured by conducting a probabilistic 
Publication: Bulletin of the World Health Organization; Type: Research 
Article ID: BLT.19.243584 
Page 5 of 18 
sensitivity analysis, which involved representing all uncertain parameters as probability 
distributions and propagating uncertainty using Monte Carlo simulations.19 The analysis was 
performed for Ethiopia and South Africa. Bootstrapping was used to account for uncertainty 
in parameters. We simulated 1000 estimates of mean costs and outcomes, which were used to 
construct 1000 simulated cost–effectiveness ratios. The results of the probabilistic sensitivity 
analysis are depicted in cost–effectiveness acceptability curves,20 which show the proportion 
of simulation results in which the short regimen was cost–effective. We assessed cost–
effectiveness using a range of willingness-to-pay thresholds, which are payment thresholds 
that a decision-maker might assign to avoiding an unfavourable MDR tuberculosis outcome. 
We considered willingness-to-pay thresholds up to US$ 100 000 for both Ethiopia and South 
Africa. 
Health-system costs 
In Ethiopia, the cost of an inpatient stay was the sum of: (i) ward staff costs; (ii) inpatient 
overhead costs, which included hospital administration costs; and (iii) a fixed hotel cost, 
which included the cost of a bed, basic supplies and meals. For the two trial sites in Ethiopia, 
inpatient overhead costs were estimated using facility financial records. In South Africa, we 
based the estimates of basic inpatient unit costs on a published study.3 We judged this source 
to be the most appropriate as data were collected from a referral hospital similar in size to the 
two hospitals involved in the STREAM trial. A sensitivity analysis was carried out to explore 
how total costs would vary if unit costs from other studies were applied.4,21,22 
Participant costs 
We estimated the mean cost of a single health facility visit from participant-reported direct 
costs. The total cost incurred in routine practice was calculated by multiplying this mean by 
the number of visits expected during usual clinical management. For Ethiopia, missing values 
in participants’ responses were imputed using chained multiple imputation as the reference 
case.23 Two response categories included imputed values: (i) expenditure on supplementary 
food; and (ii) hours worked.13 Chained imputations could not be performed for South Africa 
because of a lack of data on both the imputed values and the variables included in the 
imputation model. All analyses of participants’ cost were performed in Stata v.15.1 
(StataCorp LP., College Station, United States of America). Treatment of MDR tuberculosis 
involves an intensive phase (when five antibiotics are given daily, including an injectable) 
followed by a continuation phase (when at least four antibiotics are given orally). The 
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intensive phase is costlier for patients because health facility visits are needed for the 
injections. There is also a greater risk of medication side-effects in this phase. 
Results 
Health-system costs 
Table 2 gives details of the health-system costs for the short and long MDR tuberculosis 
treatment regimens. The cost was greater with the long than the short regimen: the total cost 
per participant in Ethiopia was US$ 6096.6 versus US$ 4552.3 (25% difference) for the two 
regimens, respectively, and in South Africa, US$ 8340.7 versus US$ 6618.0 (21% 
difference), respectively. Overall, 61% (US$ 944.3) the reduction occurred in the 
continuation phase in Ethiopia, as did 85% (US$ 1461.3) in South Africa. In Ethiopia, the 
saving was primarily due to lower costs for social support (35%; US$ 545.2), laboratory tests 
(30%; US$ 456.9) and medications (20%; US$ 301.7), whereas in South Africa, the reduction 
was primarily due to lower medication (67%; US$ 1157.0) and staff costs (36%; US$ 619.1; 
Table 2). For the short regimen, the cost of cardiac monitoring per participant was US$ 149.5 
in Ethiopia and US$ 150.9 in South Africa. 
In Ethiopia, there was no substantial difference in the mean medication cost per 
participant between the regimens: it was US$ 1361.3 (95% confidence interval, CI: 1255.7 to 
1465.8) for the short regimen and US$ 1663.0 (95% CI: 1536.4 to 1790.4) for the long 
regimen. In South Africa, however, there was a significant difference: the mean medication 
cost per participant was US$ 433.9 (95% CI: 385.4 to 481.1) for the short regimen and 
US$ 1590.9 (95% CI: 1283.5 to 1899.3) for the long regimen. 
The largest expenditure category for both regimens was inpatient costs, even when the 
unit cost was varied in a sensitivity analysis.13 In Ethiopia, the mean inpatient stay was 
9.62 weeks (95% CI: 9.01 to 10.24) for the short regimen and 9.64 weeks (95% CI: 8.74 to 
10.52) for the long regimen. In South Africa, it was 9.43 weeks (95% CI: 8.30 to 10.56) for 
the short regimen and 9.02 weeks (95% CI: 7.51 to 10.52) for the long regimen. 
Consequently, changing to the short regimen had no meaningful implication for inpatient 
costs. The mean cost of a serious adverse event in Ethiopia was higher for the long 
(US$ 82.1; 95% CI: 46.0 to 118.2) than the short regimen (US$ 15.7; 95% CI: 1.2 to 30.2; 
Table 2). Although each episode was expensive to treat, the cost of serious adverse events did 
not substantially influence cost savings with the short regimen as few participants 
experienced them. 
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Our probabilistic sensitivity analysis showed that the short regimen is highly likely to 
be cost–effective (Fig. 1 and Fig. 2). However, the probability it would be cost–effective 
declined as the value decision-makers placed on avoiding an unfavourable outcome 
increased: the probability was greater than 95% if that value were less than US$ 19 000 in 
Ethiopia and less than US$ 14 500 in South Africa. Even when the value was as high as 
US$ 100 000, the probability was still above 77% for both countries. 
Participant costs 
Data for the participant-perspective analysis were available from 111 trial participants in 
Ethiopia and 14 in South Africa (Doris Goodwin Hospital). The mean cost per participant of 
a health facility visit was US$ 1.1 in Ethiopia (US$ 0.8 for transport and US$ 0.4 for food) 
and US$ 4.9 in South Africa (US$ 3.6 for transport and US$ 1.3 for food). In Ethiopia, as the 
short regimen was 11 months shorter than the long regimen, the cost saving per participant 
was US$ 12.5 over the treatment course. In South Africa, the difference was 13 months, 
giving a saving of US$ 64.0. 
In Ethiopia, 94% (104/111) of participants reported spending on supplementary food 
(e.g. meat, fruit and energy drinks). The cumulative mean per participant was US$ 549.1 
(95% CI: 426.7 to 671.6) for the long regimen and US$ 323.6 (95% CI: 250.6 to 396.7) for 
the short regimen; the difference was US$ 225.5 (95% CI: 133.0 to 297.1; Fig. 3). The total 
direct costs per participant were US$ 575.4 for the long regimen and US$ 337.3 for the short 
regimen. Consequently, the total direct cost saving per participant with the short regimen was 
US$ 238.0, of which 95% related to reduced spending on supplementary food.13 
Participants in Ethiopia were unable or unwilling to provide estimates of their typical 
monthly income. However, many reported the number of hours they were able to work 
(Fig. 4). By 48 weeks after treatment initiation, an estimated 52% of participants on the short 
regimen were able to work at least 8 hours per day compared with 30% on the long regimen. 
Overall, the mean additional time worked per participant on the short regimen during the 
132 weeks of treatment and follow-up was 667 hours (95% CI: 193 to 1127). This increase in 
productivity corresponded to a saving in indirect costs of US$ 175.7 per participant based on 
the reported incomes of MDR tuberculosis patients in Ethiopia.24 Consequently, the total cost 
saving per participant in Ethiopia was US$ 413.7 – 42% related to indirect costs and 58% 
related to direct costs. Insufficient data were available to estimate supplementary food 
expenditure and hours worked by participants in South Africa.13 
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Discussion 
Using data from the phase-III, randomized, controlled STREAM trial, we found that the short 
regimen of MDR tuberculosis treatment led to substantial savings for both participants and 
the health-care system. Although this was intuitively expected, there were important, 
unexpected findings on the timing and drivers of these savings. We found that participant 
cost savings in Ethiopia were mainly due to lower expenditure on supplementary food and 
increased working hours; savings from fewer health facility visits were less important. The 
increase in working hours accrued largely between treatment weeks 16 and 32, when 
participants on the long regimen were receiving injectable drugs and those on the short 
regimen were not. Supplementary food expenditure diverged largely during weeks 48 to 84, 
when only those on the long regimen were still receiving treatment. These may be crucial 
benefits for MDR tuberculosis patients and their families given their typical socioeconomic 
situation. We estimated the mean cost to all trial participants in Ethiopia was 30 to 50% of 
their income,24 suggesting that a substantial number experienced catastrophic costs, though 
many fewer on the short regimen were affected. 
Clinical and health-system factors, such as wages, prices and models of care, can also 
influence savings. For example, if inpatient care were maintained while patients receive 
injectable medications, switching to the short regimen (which involves four fewer weeks of 
injectable therapy) in South Africa would result in an additional saving of US$ 1958 per 
patient, thereby increasing the total saving to US$ 3681 per patient. We also estimated the 
effect on health-system costs in South Africa if outpatient care were the norm, which is 
increasingly common.25,26 Using published outpatient unit costs,3 the total health-system costs 
of the long and short regimens would be US$ 5600 and US$ 3415 per patient, respectively – 
both substantially less than for inpatient care (Table 2). 
Cost savings also depended on the choice of antibiotics. In South Africa (but not 
Ethiopia), terizidone was used in the long regimen, whereas the medications used in the short 
regimen were heavily regulated, which gave substantial cost savings. Although participants 
on the short regimen needed cardiac monitoring due to the increased risk of a prolonged QTc 
interval, the cost of US$ 150 per participant was greatly outweighed by other savings. 
Our study has limitations. Considerable data on participants’ responses were missing, 
particularly from South Africa where operational problems delayed data collection and 
reduced participants’ willingness to provide economic data. However, sensitivity analyses 
showed that these missing data had little impact on our findings.13 Moreover, the experience 
Publication: Bulletin of the World Health Organization; Type: Research 
Article ID: BLT.19.243584 
Page 9 of 18 
of trial participants was different from that of patients seen in routine practice, which could 
have influenced costs: the number of visits was different, and some support was provided 
(e.g. free or subsidized transport). Where possible, we adjusted our analysis to account for 
such differences. We did not include the costs or consequences of treatment failure, such as 
retreatment or increased morbidity and mortality. Short regimens could lead to an increased 
likelihood of retreatment or to more extensive drug resistance. However, no significant 
difference in unfavourable outcomes between the regimens was observed. 
One limitation of our cost–effectiveness analysis is that we cannot definitively assert 
that the short regimen is cost–effective because the precise value placed on avoiding 
unfavourable outcomes was not available. Further research is needed to determine this value, 
which would involve estimating the costs and consequences of unfavourable outcomes. 
Nevertheless, the value would have to be hundreds of thousands of dollars before the short 
regimen becomes unlikely to be cost–effective. 
In South Africa, we were unable to estimate the cost of serious adverse events 
because care records were not available. However, given the marginal difference in serious 
adverse events rates between regimens,9 it is unlikely they would have meaningfully changed 
our findings. Serious metabolic and nutritional disorders were more frequent in Ethiopia than 
in the trial overall (29%; 12/41, versus 9%; 12/141, respectively),9 probably because the 
injectable drug used was capreomycin, which has more metabolic side-effects than the 
kanamycin and amikacin used at other sites. 
Despite these limitations, our study provides detailed comparative information on the 
health-system costs of treating MDR tuberculosis patients with different regimens. 
Furthermore, we found that the short regimen is associated with substantial savings for the 
health system, which are influenced by the local model of care. Nevertheless, the short 
regimen is highly likely to be cost–effective in other low- and middle-income countries. In 
addition, participants were able to return to work sooner, thereby helping safeguard the 
financial wellbeing of their households. 
New evidence on the efficacy of short, all oral regimens for MDR tuberculosis will 
influence WHO’s considerations on whether to recommend a transition away from long 
regimens and the use of injectables.12 As we demonstrated, the economic implications of 
short regimens will vary considerably between countries. These variations are unlikely to 
change the overall economic case for shorter regimens, but they will be important for 
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optimizing implementation. The switch to shorter regimens will involve stakeholders 
examining the local importance of the different cost categories we investigated in Ethiopia 
and South Africa and reflecting on their relevance for estimating budgets and developing 
implementation plans. 
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Table 1. Participants providing information on direct costs of multidrug-
resistant tuberculosis treatment, STREAM trial, Ethiopia and South Africa, 
2012–2018 
Information 
provided 
No. of participants 
Ethiopia  South Africa 
St Peter’s 
Specialized 
Hospital (n = 68) 
Armauer 
Hansen 
Research 
Institute 
Hospital 
(n = 51) 
Doris 
Goodwin 
Hospital 
(n = 14) 
Sizwe 
Tropical 
Diseases 
Hospital 
(n = 33) 
Direct costs of 
visiting health 
facility 
65 46  14 18 
Cost of 
supplementary food 
at treatment week: 
     
12 35 20  9 2 
24 50 25  12 5 
36 48 26  13 6 
48 53 22  13 2 
60 57 30  0 0 
72 59 36  0 0 
84 54 38  11 3 
96 48 35  4 7 
108 50 42  2 2 
120 49 41  6 2 
132 61 39  14 0 
No. of working 
hours at treatment 
week: 
     
24 56 26  11 6 
48 56 30  13 9 
72 53 37  13 6 
96 39 38  5 0 
120 47 41  6 0 
132 60 38  0 5 
STREAM: standard treatment regimen of antituberculosis drugs for patients with multidrug-resistant 
tuberculosis. 
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Table 2. Health-system costs of short and long multidrug-resistant 
tuberculosis treatment, STREAM trial, Ethiopia and South Africa, 2012–2018 
Cost element, by 
country 
Health-system costs in US$ per patient (% of country total) 
Long regimena  Short regimena 
Intensive 
phasec 
Continuation 
phasec 
Total for two 
phases 
 Intensive 
phasec 
Continuation 
phasec 
Total for two 
phases
Ethiopia       
Inpatient stay 2090.1 (50) 0.0 (0) 2090.1 (34)  2087.7 (59) 0.0 (0) 2087.7 (41)
Laboratory tests 381.0 (9) 469.6 (24) 850.6 (14)  197.2 (6) 196.5 (20) 393.7 (10)
Cardiac safety 
monitoring 
0.0 (0) 0.0 (0) 0.0 (0)  79.8 (2) 69.8 (7) 149.6 (3)
Medication 1153.9 (28) 509.1 (27) 1663.0 (27)  969.5 (27) 391.8 (40) 1361.3 (33)
Staff 98.5 (2) 104.7 (5) 203.2 (4)  62.7 (2) 43.6 (4) 106.3 (3)
Social support 218.1 (5) 581.5 (30) 799.6 (13)  72.7 (2) 181.7 (19) 254.4 (6)
Consumables 163.2 (4) 244.8 (13) 408.0 (7)  81.6 (2) 102.0 (10) 183.6 (4)
Serious adverse 
events 
60.5 (2) 21.6 (1) 82.1 (1)  14.1 (< 1) 1.6 (< 1) 15.7 (<
Total 4165.3 (100) 1931.3 (100) 6096.6 (100)  3565.3 (100) 987.0 (100) 4552.3 (100)
South Africa       
Inpatient stay 4284.5 (70) 0.0 (0) 4284.5 (51)  4480.2 (77) 0.0 (0) 4480.2 (68)
Laboratory tests 459.5 (8) 452.9 (20) 912.4 (11)  452.7 (8) 279.1 (35) 731.8 (11)
Cardiac safety 
monitoring 
0.0 (0) 0.0 (0) 0.0 (0)  71.0 (1) 79.9 (10) 150.9 (2)
Medication 621.0 (10) 969.9 (43) 1590.9 (19)  260.0 (4) 173.9 (22) 433.9 (6)
Staff 643.6 (11) 692.5 (31) 1336.1 (16)  500.6 (9) 216.4 (28) 717.0 (11)
Social supportd 0.0 (0) 0.0 (0) 0.0 (0)  0.0 (0) 0.0 (0) 0.0 (0)
Consumables 78.2 (1) 138.6 (6) 216.8 (3)  60.8 (1) 43.3 (5) 104.1 (2)
Total 6086.8 (100) 2253.9 (100) 8340.7 (100)  5825.3 (100) 792.7 (100) 6618.0 (100)
STREAM: standard treatment regimen of antituberculosis drugs for patients with multidrug-resistant 
tuberculosis; US$: United States dollar. 
a The long regimen lasted 20 to 22 months and the short regimen lasted 9 to 11 months. 
b Negative values indicate that costs were greater for the short than the long regimen. 
c In the intensive phase, five antibiotics are given daily (including an injectable); in the subsequent 
continuation phase, at least four antibiotics are given orally. 
d In South Africa, the cost of social support to the health system was zero because, unlike in Ethiopia, 
social support in South Africa was covered by donor funding. 
Note: In South Africa, we were unable to estimate the cost of serious adverse events because care 
records were not available. 
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Fig. 1. Probability that short multidrug-resistant tuberculosis treatment was 
more cost–effective than long treatment, by willingness to pay to avoid 
unfavourable outcomes, STREAM trial, Ethiopia, 2012–2017 
 
 
STREAM: standard treatment regimen of antituberculosis drugs for patients with multidrug-resistant 
tuberculosis; US$: United States dollar. 
Notes: Long treatment lasted 20 to 22 months and short treatment lasted 9 to 11 months. The 
willingness-to-pay threshold is the amount a decision-maker would pay to avoid an unfavourable 
outcome due to multidrug-resistant tuberculosis. For the parametric analysis, parameter values were 
simulated from distributions derived from the summary statistics of the observed data. For the 
bootstrap analysis, data were sampled with replacement values from the STREAM data set. 
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Fig. 2. Probability that short multidrug-resistant tuberculosis treatment was 
more cost–effective than long treatment, by willingness to pay to avoid 
unfavourable outcomes, STREAM trial, South Africa, 2014–2018 
 
 
STREAM: standard treatment regimen of antituberculosis drugs for patients with multidrug-resistant 
tuberculosis; US$: United States dollar. 
Notes: Long treatment lasted 20 to 22 months and short treatment lasted 9 to 11 months. The 
willingness-to-pay threshold is the amount a decision-maker would pay to avoid an unfavourable 
outcome due to multidrug-resistant tuberculosis. For the parametric analysis, parameter values were 
simulated from distributions derived from the summary statistics of the observed data. For the 
bootstrap analysis, data were sampled with replacement values from the STREAM data set 
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Fig. 3. Participants’ cumulative spending on supplementary food, by length of 
multidrug-resistant tuberculosis treatment, STREAM trial, Ethiopia, 2012–2017 
 
 
STREAM: standard treatment regimen of antituberculosis drugs for patients with multidrug-resistant 
tuberculosis; US$: United States dollar. 
Notes: The long regimen lasted around 86 weeks and the short regimen lasted around 44 weeks. The 
dots represent data collection times. The nearest data collection time after completion of the short 
regimen was in week 48 and the nearest time after completion of the long regimen was in week 96. 
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Fig. 4. Proportion of participants working at least 8 hours per day, by length of 
multidrug-resistant tuberculosis treatment, STREAM trial, Ethiopia, 2012–2017 
 
 
STREAM: standard treatment regimen of antituberculosis drugs for patients with multidrug-resistant 
tuberculosis. 
Notes: Work included schooling, housework and formal and informal work. The long regimen lasted 
around 86 weeks and the short regimen lasted around 44 weeks. All participants were hospitalized at 
randomization to treatment regimen. The percentages have been imputed as described in the 
methods section. 
 
